Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: a novel approach to enhancing anti-inflammatory and anti-fibrotic effects
International Immunopharmacology · 2025-11 · 165 · 115480
DOI: 10.1016/j.intimp.2025.115480 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025-11. Verfasst von Rabab S Hamad und 17 weiteren Autor:innen. Beteiligte Einrichtung: Biological Sciences Department, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia. Electronic address: rhamad@kfu.edu.sa. Hauptthemen laut MEDLINE: Gelatin, Chitosan, Lung, Anti-Inflammatory Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: King Faisal University, Qassim University, Deanship of Scientific Research, King Khalid University.
Abstract (Originalsprache)
This study introduces a novel dual-sensitive drug delivery system, gelatin-coated chitosan microparticles (GL-ChMPs), designed to enhance the lung targeting and therapeutic efficacy of semaglutide (SEM). GL-ChMPs were designed to respond to the acidic environment and metalloproteinases, conditions that are typical in pulmonary fibrosis. SEM-GL-ChMPs exhibited superior lung targeting and prolonged retention while minimizing systemic distribution. SEM-GL-ChMPs demonstrated 21-fold and 2-fold higher time-averaged lung drug exposure compared to free SEM solution and uncoated ChMPs, respectively. In a bleomycin-induced chronic lung injury model, SEM-GL-ChMPs effectively attenuated inflammation and fibrotic progression in lung tissues. On the inflammatory front, SEM-GL-ChMPs significantly reduced immune cell infiltration, which was accompanied by lower BALF total protein and LDH, suggesting reduced alveolar-capillary barrier disruption and cellular injury. At the molecular level, there was a marked inhibition of TLR4/NFκB signaling and a downregulation of pro-inflammatory cytokines TNF-α, IL-6, and IL-8. On the fibrotic side, SEM-GL-ChMPs resulted in a pronounced decrease in key fibrogenic mediators, including TGF-β1 and p-SMAD3, and critical markers like α-SMA and Col1a1. Histopathological analysis further reinforced these findings. The gelatin coating was designed to exploit MMP-2 overexpression in fibrotic lungs, enabling localized drug release. Our data confirmed that metalloproteinases are positively correlated with fibrosis progression, supporting the rationale for this enzyme-responsive delivery approach. Collectively, SEM-GL-ChMPs not only improved lung-specific drug delivery and retention but also effectively mitigated the hallmarks of chronic lung injury at cellular, molecular, and tissue levels. This underscores their promise as a precision-targeted, dual-sensitive platform for managing chronic inflammatory and fibrotic lung diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biological Sciences Department, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia. Electronic address: rhamad@kfu.edu.sa.
- Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Electronic address: ahmed.kira@deltauniv.edu.eg.
- Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Electronic address: sameh.saber@deltauniv.edu.eg.
- Department of Medicine, College of Medicine, Qassim University, Buraidah 51452, Saudi Arabia. Electronic address: 24426@qu.edu.sa.
- Department of Anatomy and Histology, College of Medicine, Qassim University, Buraidah 51452, Saudi Arabia. Electronic address: h.alsaykhan@qu.edu.sa.
- Department of Microbiology and Immunology, College of Medicine, Qassim University, Buraidah 51452, Saudi Arabia. Electronic address: ssahmd@qu.edu.sa.
Förderung
- King Faisal University
- Qassim University
- Deanship of Scientific Research, King Khalid University
- University of Bisha
Zitieren
APA
Hamad, R. S., Kira, A. Y., Saber, S., Alharbi, M. S., Alsaykhan, H., Ahmed, S. S., Ahmed, H. H. T., Ahmed, A., Farrag, A. A., Eissa, H., Mohamed, N. B., Khodeir, M. M., Hatem, M. M., Alghasham, A., Abdel-Reheim, M. A., Ramadan, M., Sameh, A., & Elmorsy, E. A. (2025). Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: a novel approach to enhancing anti-inflammatory and anti-fibrotic effects. International Immunopharmacology, 165, 115480. https://doi.org/10.1016/j.intimp.2025.115480
Vancouver
Hamad RS, Kira AY, Saber S, Alharbi MS, Alsaykhan H, Ahmed SS, et al. Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: a novel approach to enhancing anti-inflammatory and anti-fibrotic effects. International Immunopharmacology. 2025;165:115480. doi:10.1016/j.intimp.2025.115480
BibTeX
@article{Hamad2025,
author = {Hamad, Rabab S and Kira, Ahmed Y and Saber, Sameh and Alharbi, Mariam S and Alsaykhan, Hamad and Ahmed, Syed Suhail and Ahmed, Hagir H T and Ahmed, Amel and Farrag, Alshaimaa A and Eissa, Hanan and Mohamed, Nahla B and Khodeir, Mostafa M and Hatem, Manal Mohamed and Alghasham, Abdullah and Abdel-Reheim, Mustafa Ahmed and Ramadan, Mohamed and Sameh, Ahmed and Elmorsy, Elsayed A},
title = {Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: a novel approach to enhancing anti-inflammatory and anti-fibrotic effects},
journal = {International Immunopharmacology},
year = {2025},
volume = {165},
pages = {115480},
doi = {10.1016/j.intimp.2025.115480}
}
EUVIMED